ATE249463T1
(en)
|
1995-11-17 |
2003-09-15 |
Biotechnolog Forschung Gmbh |
EPOTHILONE DERIVATIVES, PRODUCTION AND USE
|
RU2198173C2
(en)
*
|
1996-11-18 |
2003-02-10 |
Гезелльшафт Фюр Биотехнологише Форшунг Мбх (Гбф) |
Epotylones c, d, e and f, their synthesis and agents based on thereof
|
US6867305B2
(en)
|
1996-12-03 |
2005-03-15 |
Sloan-Kettering Institute For Cancer Research |
Synthesis of epothilones, intermediates thereto and analogues thereof
|
EP0977563B1
(en)
|
1996-12-03 |
2005-10-12 |
Sloan-Kettering Institute For Cancer Research |
Synthesis of epothilones, intermediates thereto, analogues and uses thereof
|
US6204388B1
(en)
|
1996-12-03 |
2001-03-20 |
Sloan-Kettering Institute For Cancer Research |
Synthesis of epothilones, intermediates thereto and analogues thereof
|
US6380394B1
(en)
|
1996-12-13 |
2002-04-30 |
The Scripps Research Institute |
Epothilone analogs
|
US6441186B1
(en)
|
1996-12-13 |
2002-08-27 |
The Scripps Research Institute |
Epothilone analogs
|
US6660758B1
(en)
|
1996-12-13 |
2003-12-09 |
The Scripps Research Institute |
Epothilone analogs
|
US6605599B1
(en)
|
1997-07-08 |
2003-08-12 |
Bristol-Myers Squibb Company |
Epothilone derivatives
|
ES2290993T3
(en)
|
1997-08-09 |
2008-02-16 |
Bayer Schering Pharma Aktiengesellschaft |
NEW DERIVATIVES OF EPOTILONE, PROCESS FOR ITS PRODUCTION AND ITS PHARMACEUTICAL USE.
|
US6320045B1
(en)
|
1997-12-04 |
2001-11-20 |
Bristol-Myers Squibb Company |
Process for the reduction of oxiranyl epothilones to olefinic epothilones
|
US6365749B1
(en)
|
1997-12-04 |
2002-04-02 |
Bristol-Myers Squibb Company |
Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
|
US6683100B2
(en)
|
1999-01-19 |
2004-01-27 |
Novartis Ag |
Organic compounds
|
US6194181B1
(en)
|
1998-02-19 |
2001-02-27 |
Novartis Ag |
Fermentative preparation process for and crystal forms of cytostatics
|
FR2775187B1
(en)
|
1998-02-25 |
2003-02-21 |
Novartis Ag |
USE OF EPOTHILONE B FOR THE MANUFACTURE OF AN ANTIPROLIFERATIVE PHARMACEUTICAL PREPARATION AND A COMPOSITION COMPRISING EPOTHILONE B AS AN IN VIVO ANTIPROLIFERATIVE AGENT
|
US6399638B1
(en)
|
1998-04-21 |
2002-06-04 |
Bristol-Myers Squibb Company |
12,13-modified epothilone derivatives
|
US6498257B1
(en)
|
1998-04-21 |
2002-12-24 |
Bristol-Myers Squibb Company |
2,3-olefinic epothilone derivatives
|
GB9810659D0
(en)
|
1998-05-18 |
1998-07-15 |
Ciba Geigy Ag |
Organic compounds
|
DE19826988A1
(en)
*
|
1998-06-18 |
1999-12-23 |
Biotechnolog Forschung Gmbh |
Epothilone minor components
|
WO1999067253A2
(en)
*
|
1998-06-22 |
1999-12-29 |
Novartis Ag |
Desmethyl epothilones
|
US6303342B1
(en)
|
1998-11-20 |
2001-10-16 |
Kason Biosciences, Inc. |
Recombinant methods and materials for producing epothilones C and D
|
US6410301B1
(en)
|
1998-11-20 |
2002-06-25 |
Kosan Biosciences, Inc. |
Myxococcus host cells for the production of epothilones
|
US6780620B1
(en)
|
1998-12-23 |
2004-08-24 |
Bristol-Myers Squibb Company |
Microbial transformation method for the preparation of an epothilone
|
US6596875B2
(en)
|
2000-02-07 |
2003-07-22 |
James David White |
Method for synthesizing epothilones and epothilone analogs
|
PL350190A1
(en)
|
1999-02-11 |
2002-11-18 |
Schering Ag |
Epothilon derivatives, method for the production and the use thereof as pharmaceuticals
|
DE60006649T2
(en)
|
1999-02-22 |
2004-09-30 |
GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) |
C-21 MODIFIED EPOTHILONE
|
US6291684B1
(en)
|
1999-03-29 |
2001-09-18 |
Bristol-Myers Squibb Company |
Process for the preparation of aziridinyl epothilones from oxiranyl epothilones
|
US7125893B1
(en)
|
1999-04-30 |
2006-10-24 |
Schering Ag |
6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations
|
EP2289549A3
(en)
|
1999-10-01 |
2011-06-15 |
Immunogen, Inc. |
Immunoconjugates for treating cancer
|
US6518421B1
(en)
|
2000-03-20 |
2003-02-11 |
Bristol-Myers Squibb Company |
Process for the preparation of epothilone analogs
|
US6593115B2
(en)
|
2000-03-24 |
2003-07-15 |
Bristol-Myers Squibb Co. |
Preparation of epothilone intermediates
|
UA75365C2
(en)
*
|
2000-08-16 |
2006-04-17 |
Bristol Myers Squibb Co |
Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
|
MXPA03006485A
(en)
|
2001-01-25 |
2003-09-22 |
Bristol Myers Squibb Co |
Parenteral formulation containing epothilone analogs.
|
NZ526870A
(en)
|
2001-01-25 |
2005-11-25 |
Bristol Myers Squibb Co |
Methods of administering epothilone analogs for the treatment of cancer
|
NZ526871A
(en)
*
|
2001-01-25 |
2006-01-27 |
Bristol Myers Squibb Co |
Pharmaceutical dosage forms of epothilones for oral administration
|
JP2004522771A
(en)
|
2001-02-20 |
2004-07-29 |
ブリストル−マイヤーズ スクイブ カンパニー |
Epothilone derivatives for the treatment of refractory tumors
|
WO2002066038A1
(en)
|
2001-02-20 |
2002-08-29 |
Bristol-Myers Squibb Company |
Treatment of refractory tumors using epothilone derivatives
|
DE60213884T2
(en)
*
|
2001-02-27 |
2007-02-22 |
GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) |
Process for the preparation of epothilones
|
EP1383490B1
(en)
|
2001-03-14 |
2012-04-25 |
Bristol-Myers Squibb Company |
Combination of an epothilone analog and chemotherapeutic agents for the treatment of proliferative diseases
|
MXPA03010909A
(en)
|
2001-06-01 |
2004-02-17 |
Bristol Myers Squibb Co |
Epothilone derivatives.
|
TWI315982B
(en)
|
2001-07-19 |
2009-10-21 |
Novartis Ag |
Combinations comprising epothilones and pharmaceutical uses thereof
|
MXPA04006822A
(en)
|
2002-01-14 |
2004-12-08 |
Novartis Ag |
Combinations comprising epothilones and anti-metabolites.
|
ES2337134T3
(en)
|
2002-03-12 |
2010-04-21 |
Bristol-Myers Squibb Company |
DERIVATIVES OF C3-CIANO-EPOTILONE.
|
US7211593B2
(en)
|
2002-03-12 |
2007-05-01 |
Bristol-Myers Squibb Co. |
C12-cyano epothilone derivatives
|
TW200403994A
(en)
|
2002-04-04 |
2004-03-16 |
Bristol Myers Squibb Co |
Oral administration of EPOTHILONES
|
TW200400191A
(en)
|
2002-05-15 |
2004-01-01 |
Bristol Myers Squibb Co |
Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
|
WO2003105828A1
(en)
|
2002-06-14 |
2003-12-24 |
Bristol-Myers Squibb Company |
Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
|
US7172884B2
(en)
|
2002-09-23 |
2007-02-06 |
Bristol-Myers Squibb Company |
Methods for the preparation, isolation and purification of epothilone B, and x-ray crystal structures of epothilone B
|
DK2253614T3
(en)
|
2004-04-07 |
2013-01-07 |
Novartis Ag |
IAP inhibitors
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
AU2006294850A1
(en)
|
2005-09-27 |
2007-04-05 |
Novartis Ag |
Carboxyamine compounds and their use in the treatment of HDAC dependent diseases
|
JP2009516671A
(en)
|
2005-11-21 |
2009-04-23 |
ノバルティス アクチエンゲゼルシャフト |
Neuroendocrine tumor treatment using mTOR inhibitors
|
GB0605120D0
(en)
|
2006-03-14 |
2006-04-26 |
Novartis Ag |
Organic Compounds
|
EP2606890A1
(en)
|
2006-04-05 |
2013-06-26 |
Novartis AG |
Combinations comprising BCR-ABL/C-KIT/PDGF-R TK inhibitors for treating cancer
|
MX2008012715A
(en)
|
2006-04-05 |
2008-10-14 |
Novartis Ag |
Combinations of therapeutic agents for treating cancer.
|
NZ572299A
(en)
|
2006-05-09 |
2010-07-30 |
Novartis Ag |
Combination comprising a substituted 3,5-diphenyl-1,2,4-triazole and a platinum compound and use thereof
|
RU2009115954A
(en)
|
2006-09-29 |
2010-11-10 |
Новартис АГ (CH) |
Pyrazolopyrimidines as P13K Lipid Kinase Inhibitors
|
WO2008100985A2
(en)
|
2007-02-15 |
2008-08-21 |
Novartis Ag |
Combination of lbh589 with other therapeutic agents for treating cancer
|
MX2010010525A
(en)
|
2008-03-24 |
2010-10-25 |
Novartis Ag |
Arylsulfonamide-based matrix metalloprotease inhibitors.
|
GEP20125708B
(en)
|
2008-03-26 |
2012-12-10 |
Novartis Ag |
Hydroxamate-based inhibitors of deacetylases b
|
WO2010083617A1
(en)
|
2009-01-21 |
2010-07-29 |
Oncalis Ag |
Pyrazolopyrimidines as protein kinase inhibitors
|
DK2391366T3
(en)
|
2009-01-29 |
2013-01-07 |
Novartis Ag |
Substituted benzimidazoles for the treatment of astrocytomas
|
JP5456891B2
(en)
|
2009-06-26 |
2014-04-02 |
ノバルティス アーゲー |
1,3-disubstituted imidazolidin-2-one derivatives as CYP17 inhibitors
|
US8389526B2
(en)
|
2009-08-07 |
2013-03-05 |
Novartis Ag |
3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
|
MX2012001838A
(en)
|
2009-08-12 |
2012-02-29 |
Novartis Ag |
Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation.
|
AU2010284972A1
(en)
|
2009-08-20 |
2012-03-08 |
Novartis Ag |
Heterocyclic oxime compounds
|
AU2010288534A1
(en)
|
2009-08-26 |
2012-03-15 |
Novartis Ag |
Tetra-substituted heteroaryl compounds and their use as MDM2 and/or MDM4 modulators
|
CA2779935A1
(en)
|
2009-11-04 |
2011-05-12 |
Novartis Ag |
Heterocyclic sulfonamide derivatives useful as mek inhibitors
|
GEP20135998B
(en)
|
2009-12-08 |
2013-12-25 |
Novartis Ag |
Heterocyclic sulfonamide derivatives
|
US8440693B2
(en)
|
2009-12-22 |
2013-05-14 |
Novartis Ag |
Substituted isoquinolinones and quinazolinones
|
CU24130B1
(en)
|
2009-12-22 |
2015-09-29 |
Novartis Ag |
ISOQUINOLINONES AND REPLACED QUINAZOLINONES
|
EP3566719A1
(en)
|
2010-05-18 |
2019-11-13 |
Cerulean Pharma Inc. |
Compositions and methods for treatment of autoimmune and other diseases
|
UA112517C2
(en)
|
2010-07-06 |
2016-09-26 |
Новартіс Аг |
TETRAHYDROPYRIDOPYRIMIDINE DERIVATIVES
|
WO2012035078A1
(en)
|
2010-09-16 |
2012-03-22 |
Novartis Ag |
17α-HYDROXYLASE/C17,20-LYASE INHIBITORS
|
WO2012107500A1
(en)
|
2011-02-10 |
2012-08-16 |
Novartis Ag |
[1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
|
CN102633792A
(en)
*
|
2011-02-15 |
2012-08-15 |
天津尚德药缘科技有限公司 |
Method for preparing epothilone D and B
|
EP2702052B1
(en)
|
2011-04-28 |
2017-10-18 |
Novartis AG |
17alpha-hydroxylase/c17,20-lyase inhibitors
|
EA201391820A1
(en)
|
2011-06-09 |
2014-12-30 |
Новартис Аг |
HETEROCYCLIC SULPHONAMIDE DERIVATIVES
|
CN106110332B
(en)
|
2011-06-10 |
2018-11-30 |
梅尔莎纳医疗公司 |
Protein-polymer-drug conjugate
|
US8859586B2
(en)
|
2011-06-20 |
2014-10-14 |
Novartis Ag |
Cyclohexyl isoquinolinone compounds
|
US8859535B2
(en)
|
2011-06-20 |
2014-10-14 |
Novartis Ag |
Hydroxy substituted isoquinolinone derivatives
|
MX2013015001A
(en)
|
2011-06-27 |
2014-03-31 |
Novartis Ag |
Solid forms and salts of tetrahydro-pyrido-pyrimidine derivatives.
|
JP5957526B2
(en)
|
2011-09-15 |
2016-07-27 |
ノバルティス アーゲー |
6-Substituted 3- (quinolin-6-ylthio)-[1,2,4] triazolo [4,3-A] pyrazine as tyrosine kinase
|
EP2785717B1
(en)
|
2011-11-29 |
2016-01-13 |
Novartis AG |
Pyrazolopyrrolidine compounds
|
US20150148377A1
(en)
|
2011-12-22 |
2015-05-28 |
Novartis Ag |
Quinoline Derivatives
|
AP4055A
(en)
|
2011-12-22 |
2017-03-07 |
Novartis Ag |
Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives
|
EP2794591A1
(en)
|
2011-12-23 |
2014-10-29 |
Novartis AG |
Compounds for inhibiting the interaction of bcl2 with binding partners
|
KR20140107574A
(en)
|
2011-12-23 |
2014-09-04 |
노파르티스 아게 |
Compounds for inhibiting the interaction of bcl2 with binding partners
|
CA2859862A1
(en)
|
2011-12-23 |
2013-06-27 |
Novartis Ag |
Compounds for inhibiting the interaction of bcl2 with binding partners
|
MX2014007732A
(en)
|
2011-12-23 |
2015-01-12 |
Novartis Ag |
Compounds for inhibiting the interaction of bcl2 with binding partners.
|
AU2012355615A1
(en)
|
2011-12-23 |
2014-07-10 |
Novartis Ag |
Compounds for inhibiting the interaction of BCL2 with binding partners
|
US8815926B2
(en)
|
2012-01-26 |
2014-08-26 |
Novartis Ag |
Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases
|
BR112014027181A2
(en)
|
2012-05-15 |
2017-06-27 |
Novartis Ag |
benzamide derivatives for inhibition of abl1, abl2 and bcr-abl1 activity
|
PL2900637T3
(en)
|
2012-05-15 |
2018-01-31 |
Novartis Ag |
Thiazole or imidazole substituted pyrimidine, pyridine and pyrazine amide derivatives and related compounds as abl1, abl2 and bcr-abl1 inhibitors for the treatment of cancer, specific viral infections and specific cns disorders
|
SG11201407152XA
(en)
|
2012-05-15 |
2014-11-27 |
Novartis Ag |
Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
|
KR20150008406A
(en)
|
2012-05-15 |
2015-01-22 |
노파르티스 아게 |
Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
|
JP6171003B2
(en)
|
2012-05-24 |
2017-07-26 |
ノバルティス アーゲー |
Pyrrolopyrrolidinone compounds
|
CN104582732A
(en)
|
2012-06-15 |
2015-04-29 |
布里格姆及妇女医院股份有限公司 |
Compositions for treating cancer and methods for making the same
|
SG11201502452RA
(en)
|
2012-10-02 |
2015-05-28 |
Epitherapeutics Aps |
Inhibitors of histone demethylases
|
TW201422625A
(en)
|
2012-11-26 |
2014-06-16 |
Novartis Ag |
Solid form of dihydro-pyrido-oxazine derivative
|
CA2892863C
(en)
|
2012-12-10 |
2022-03-15 |
Mersana Therapeutics, Inc. |
Polymeric scaffold based on phf for targeted drug delivery
|
US9872918B2
(en)
|
2012-12-12 |
2018-01-23 |
Mersana Therapeutics, Inc. |
Hydroxyl-polymer-drug-protein conjugates
|
US9556180B2
(en)
|
2013-01-22 |
2017-01-31 |
Novartis Ag |
Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the P53/MDM2 interaction
|
US9403827B2
(en)
|
2013-01-22 |
2016-08-02 |
Novartis Ag |
Substituted purinone compounds
|
WO2014128612A1
(en)
|
2013-02-20 |
2014-08-28 |
Novartis Ag |
Quinazolin-4-one derivatives
|
EA030451B1
(en)
|
2013-02-27 |
2018-08-31 |
Эпитерапьютикс Апс |
Inhibitors of histone demethylases
|
CN103232464B
(en)
*
|
2013-03-29 |
2015-08-19 |
四川农业大学 |
Taxoid compound and preparation thereof and the application in cancer therapy drug
|
US20150018376A1
(en)
|
2013-05-17 |
2015-01-15 |
Novartis Ag |
Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof
|
US20160128988A1
(en)
|
2013-06-11 |
2016-05-12 |
Bayer Pharma Aktiengesellschaft |
Combinations for the treatment of cancer comprising a mps-1 kinase inhibitor and a mitotic inhibitor
|
UY35675A
(en)
|
2013-07-24 |
2015-02-27 |
Novartis Ag |
SUBSTITUTED DERIVATIVES OF QUINAZOLIN-4-ONA
|
US9227969B2
(en)
|
2013-08-14 |
2016-01-05 |
Novartis Ag |
Compounds and compositions as inhibitors of MEK
|
WO2015022664A1
(en)
|
2013-08-14 |
2015-02-19 |
Novartis Ag |
Compounds and compositions as inhibitors of mek
|
WO2015022663A1
(en)
|
2013-08-14 |
2015-02-19 |
Novartis Ag |
Compounds and compositions as inhibitors of mek
|
US9670194B2
(en)
|
2013-09-22 |
2017-06-06 |
Calitor Sciences, Llc |
Substituted aminopyrimidine compounds and methods of use
|
JP6420331B2
(en)
|
2013-10-11 |
2018-11-07 |
メルサナ セラピューティクス,インコーポレイティド |
Protein-polymer-drug conjugate
|
MX2016004659A
(en)
|
2013-10-11 |
2017-08-02 |
Asana Biosciences Llc |
Protein-polymer-drug conjugates.
|
MX2016012574A
(en)
|
2014-03-28 |
2017-09-26 |
Calitor Sciences Llc |
Substituted heteroaryl compounds and methods of use.
|
CA2943824A1
(en)
|
2014-03-31 |
2015-10-08 |
Gilead Sciences, Inc. |
Inhibitors of histone demethylases
|
AU2015241198A1
(en)
|
2014-04-03 |
2016-11-17 |
Invictus Oncology Pvt. Ltd. |
Supramolecular combinatorial therapeutics
|
EA201790154A1
(en)
|
2014-08-27 |
2017-08-31 |
Джилид Сайэнс, Инк. |
COMPOUNDS AND METHODS FOR INHIBITING HISTONAL DEMETYLASES
|
US9938257B2
(en)
|
2015-09-11 |
2018-04-10 |
Calitor Sciences, Llc |
Substituted heteroaryl compounds and methods of use
|
US11617799B2
(en)
|
2016-06-27 |
2023-04-04 |
Tagworks Pharmaceuticals B.V. |
Cleavable tetrazine used in bio-orthogonal drug activation
|
US11135307B2
(en)
|
2016-11-23 |
2021-10-05 |
Mersana Therapeutics, Inc. |
Peptide-containing linkers for antibody-drug conjugates
|
CN111315414A
(en)
|
2017-06-22 |
2020-06-19 |
梅尔莎纳医疗公司 |
Methods of producing drug-loaded polymer scaffolds and protein-polymer-drug conjugates
|
US10683297B2
(en)
|
2017-11-19 |
2020-06-16 |
Calitor Sciences, Llc |
Substituted heteroaryl compounds and methods of use
|
AU2019209960B2
(en)
|
2018-01-20 |
2023-11-23 |
Sunshine Lake Pharma Co., Ltd. |
Substituted aminopyrimidine compounds and methods of use
|
AU2019262521B2
(en)
|
2018-05-04 |
2024-04-18 |
Tagworks Pharmaceuticals B.V. |
Compounds comprising a linker for increasing transcyclooctene stability
|
US20210299286A1
(en)
|
2018-05-04 |
2021-09-30 |
Tagworks Pharmaceuticals B.V. |
Tetrazines for high click conjugation yield in vivo and high click release yield
|
MX2021004906A
(en)
|
2018-10-29 |
2021-09-10 |
Mersana Therapeutics Inc |
Cysteine engineered antibody-drug conjugates with peptide-containing linkers.
|
FR3087650B1
(en)
|
2018-10-31 |
2021-01-29 |
Bio Even |
FLAVINE ADENINE DINUCLEOTIDE (FAD) FOR USE FOR THE PREVENTION AND / OR TREATMENT OF CANCER
|
IL289094A
(en)
|
2019-06-17 |
2022-02-01 |
Tagworks Pharmaceuticals B V |
Tetrazines for high click release speed and yield
|
CN115135628A
(en)
|
2019-06-17 |
2022-09-30 |
泰克沃尔科斯制药有限公司 |
Compounds for fast and efficient click release
|
EP4399283A2
(en)
|
2021-09-06 |
2024-07-17 |
Veraxa Biotech GmbH |
Novel aminoacyl-trna synthetase variants for genetic code expansion in eukaryotes
|
EP4186529A1
(en)
|
2021-11-25 |
2023-05-31 |
Veraxa Biotech GmbH |
Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion
|
AU2022395626A1
(en)
|
2021-11-25 |
2024-05-30 |
Veraxa Biotech Gmbh |
Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion
|
CN118574641A
(en)
|
2021-12-08 |
2024-08-30 |
欧洲分子生物学实验室 |
Hydrophilic tetrazine functionalized supports for preparing targeted conjugates
|
DK4314031T3
(en)
|
2022-02-15 |
2024-06-17 |
Tagworks Pharmaceuticals B V |
MASKED IL12 PROTEIN
|
WO2024013723A1
(en)
|
2022-07-15 |
2024-01-18 |
Pheon Therapeutics Ltd |
Antibody drug conjugates that bind cdcp1 and uses thereof
|
WO2024080872A1
(en)
|
2022-10-12 |
2024-04-18 |
Tagworks Pharmaceuticals B.V. |
Strained bicyclononenes
|
WO2024153789A1
(en)
|
2023-01-20 |
2024-07-25 |
Basf Se |
Stabilized biopolymer composition, their manufacture and use
|